JP2023525981A - 肺炎症および間質性肺疾患を処置するためのレリグリタゾン - Google Patents

肺炎症および間質性肺疾患を処置するためのレリグリタゾン Download PDF

Info

Publication number
JP2023525981A
JP2023525981A JP2022566063A JP2022566063A JP2023525981A JP 2023525981 A JP2023525981 A JP 2023525981A JP 2022566063 A JP2022566063 A JP 2022566063A JP 2022566063 A JP2022566063 A JP 2022566063A JP 2023525981 A JP2023525981 A JP 2023525981A
Authority
JP
Japan
Prior art keywords
dione
ethoxy
phenyl
methyl
thiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525981A5 (https=
Inventor
ペデモンテ， マルク マルティネル
ラランサ， マリア ピラール ピスクエタ
サウラ， アナ ヴィラルタ
ロペス， エステファニア トラベル
ポリ， ソニア マリア
ウセロス， ヌリア イスキエルド
Original Assignee
ミノリックス セラピューティクス エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノリックス セラピューティクス エセ．エレ． filed Critical ミノリックス セラピューティクス エセ．エレ．
Publication of JP2023525981A publication Critical patent/JP2023525981A/ja
Publication of JP2023525981A5 publication Critical patent/JP2023525981A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022566063A 2020-04-30 2021-04-30 肺炎症および間質性肺疾患を処置するためのレリグリタゾン Pending JP2023525981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
EP20382356.2 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (2)

Publication Number Publication Date
JP2023525981A true JP2023525981A (ja) 2023-06-20
JP2023525981A5 JP2023525981A5 (https=) 2024-05-10

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566063A Pending JP2023525981A (ja) 2020-04-30 2021-04-30 肺炎症および間質性肺疾患を処置するためのレリグリタゾン

Country Status (11)

Country Link
US (1) US20230172921A1 (https=)
EP (1) EP4142720A1 (https=)
JP (1) JP2023525981A (https=)
KR (1) KR20230035522A (https=)
CN (1) CN116390725A (https=)
AU (1) AU2021265345A1 (https=)
BR (1) BR112022021951A2 (https=)
CA (1) CA3180351A1 (https=)
IL (1) IL297771A (https=)
MX (1) MX2022013021A (https=)
WO (1) WO2021220250A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4642456A1 (en) * 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529953A (ja) * 2008-08-07 2011-12-15 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療
JP2013508282A (ja) * 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
WO2019234690A1 (en) * 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
JP2020500868A (ja) * 2016-12-01 2020-01-16 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５−［［４−［２−［５−（１−ヒドロキシエチル）ピリジン−２−イル］エトキシ］フェニル］メチル］−１，３−チアゾリジン−２，４−ジオン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
EA202091120A3 (ru) 2014-04-02 2020-12-30 Минорикс Терапьютикс С.Л. Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529953A (ja) * 2008-08-07 2011-12-15 プルマゲン セラピューティクス（インフラメーション）リミテッド 呼吸器疾患の治療
JP2013508282A (ja) * 2009-10-14 2013-03-07 ジェンムス ファーマ インコーポレイティド ウイルス感染のための併用療法処置
JP2020500868A (ja) * 2016-12-01 2020-01-16 ミノリックス セラピューティクス エセ．エレ． 非アルコール性脂肪性肝疾患を処置するための５−［［４−［２−［５−（１−ヒドロキシエチル）ピリジン−２−イル］エトキシ］フェニル］メチル］−１，３−チアゾリジン−２，４−ジオン
WO2019234690A1 (en) * 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARBONI E. ET AL., MEDICAL HYPOTHESES, vol. 109776, JPN6025014801, 22 April 2020 (2020-04-22), ISSN: 0005705924 *
CIAVARELLA C. ET AL., MOLECULES, vol. 25, 2076, JPN6025014800, 29 April 2020 (2020-04-29), ISSN: 0005705925 *

Also Published As

Publication number Publication date
CA3180351A1 (en) 2021-11-04
WO2021220250A1 (en) 2021-11-04
MX2022013021A (es) 2023-01-16
IL297771A (en) 2022-12-01
CN116390725A (zh) 2023-07-04
AU2021265345A1 (en) 2022-12-08
KR20230035522A (ko) 2023-03-14
EP4142720A1 (en) 2023-03-08
US20230172921A1 (en) 2023-06-08
BR112022021951A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US20230241014A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
US20230084300A1 (en) Prevention and treatment of infections including those caused by coronavirus
US20260041660A1 (en) Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
TW202415386A (zh) 用於治療病毒感染之方法
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US20240316083A1 (en) Medicament for prevention or treatment of rhinovirus infection
US20230079150A1 (en) Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer
KR20200103056A (ko) 고사이토카인혈증 및 중증 인플루엔자의 치료 또는 예방을 위한 방법 및 화합물
JP2023525981A (ja) 肺炎症および間質性肺疾患を処置するためのレリグリタゾン
EP3892279A1 (en) Compositions for use in the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection
CN113288892A (zh) 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
HK40096631A (zh) 用於治疗肺部炎症和间质性肺病的羟基吡格列酮
EP3720440A1 (en) Treatment of rsv with combination product
US20220017614A1 (en) Anti-IL6 Agent for Treating Coronavirus Infection
EP4115885A1 (en) A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
RU2837859C1 (ru) Лечение коронавирусной инфекции
Ramezaninejad et al. The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
Hussain NOVEL THERAPEUTIC DRUG APPROACHES FOR COVID-19
EA040061B1 (ru) Комбинация для лечения и ослабления rsv инфекции и фармацевтическая композиция на ее основе

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251009